Lowering blood pressure
Each 10 mmHg lower systolic pressure cuts major cardiovascular events by about 20%.
Why high: Large randomised evidence, consistent across groups.
Meta-analysis of randomised trials · Ettehad et al., Lancet 2016
The research behind our charts and tools: what was studied, in how many people, how big the effect was and how certain we can be. Filter it, sort it, and ask Biongevity SI to explain any card.
Each 10 mmHg lower systolic pressure cuts major cardiovascular events by about 20%.
Why high: Large randomised evidence, consistent across groups.
Meta-analysis of randomised trials · Ettehad et al., Lancet 2016
Each 1 mmol/L lower LDL cuts major heart and stroke events by about a fifth.
Why high: Many large randomised trials, consistent and precise.
Meta-analysis of randomised trials · Cholesterol Treatment Trialists' Collaboration, Lancet 2010
In generally healthy adults, vitamin D did not lower cancer or cardiovascular events.
Why high: Large, well-run randomised trial — a useful 'no effect' result.
Randomised trial · Manson et al., NEJM 2019 (VITAL)
From 115 mmHg upward, every 20 mmHg higher systolic pressure roughly doubles vascular death risk (ages 40–69).
Why moderate: Observational, but very large with a strong dose–response.
Meta-analysis of prospective cohorts · Prospective Studies Collaboration, Lancet 2002
Higher Lp(a) is linked with more coronary disease; it is largely inherited, so one test is usually enough.
Why moderate: Observational, supported by genetic (Mendelian randomisation) studies.
Meta-analysis of prospective studies · Emerging Risk Factors Collaboration, JAMA 2009
Stopping by age 30 avoids almost all the excess risk; stopping at 40, 50 or 60 still gains about 9, 6 or 3 years.
Why moderate: Very long follow-up with a large, consistent effect.
Prospective cohort, 50 years of follow-up · Doll et al., BMJ 2004
In people with high triglycerides on statins, high-dose purified EPA lowered cardiovascular events.
Why moderate: One large trial; debate about the mineral-oil placebo. Not the same as over-the-counter fish oil.
Randomised trial · Bhatt et al., NEJM 2019 (REDUCE-IT)
A Mediterranean diet with extra-virgin olive oil or nuts lowered major cardiovascular events.
Why moderate: Single large trial, re-analysed after randomisation issues.
Randomised trial · Estruch et al., NEJM 2018
Consistently sleeping less than about 6–7 hours is linked with higher mortality.
Why low: Observational; sleep may reflect other illness.
Meta-analysis of prospective cohorts · Cappuccio et al., Sleep 2010
Higher CRP is associated with more coronary heart disease.
Why low: Observational; association weakens after adjustment for other risk factors.
Meta-analysis of prospective cohorts · Emerging Risk Factors Collaboration, Lancet 2010
Never smoking, healthy weight, 30+ minutes of activity, moderate alcohol and a quality diet add years.
Why low: Observational; US health professionals.
Two large prospective cohorts · Li et al., Circulation 2018
Low fitness carries a mortality risk comparable to or greater than smoking or diabetes.
Why low: Single-centre, observational; strong gradient.
Retrospective cohort (treadmill testing) · Mandsager et al., JAMA Network Open 2018
A favourable lifestyle is linked with about half the coronary risk, even with high genetic risk.
Why low: Observational; consistent across genetic risk groups.
Four prospective cohorts and studies · Khera et al., NEJM 2016
More daily steps are linked with lower mortality, levelling off around 6,000–8,000 (60+) and 8,000–10,000 (under 60).
Why low: Observational with a clear dose–response; device-measured steps.
Meta-analysis of prospective cohorts · Paluch et al., Lancet Public Health 2022
GRADE rates how certain the evidence is: High (further research is very unlikely to change it) to Very low. Summaries are curated and paraphrased from the cited papers — always check the original. Last reviewed October 2026.
Book a consultation online, or message us on WhatsApp and a coordinator will reply during clinic hours.
or call 403-250-2221